tbuckley/cabot-search huggingface dataset:
Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
Authors: Philip Zeitler, Rodolfo J. Galindo, Melanie J. Davies, Brandon K. Bergman, Vivian T. Thieu, Claudia Nicolay, Sheryl Allen, Robert J. Heine, Clare J. Lee
Journal: Diabetes Care (2024)

OBJECTIVE We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1] and A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P &amp;lt; 0.001) higher glycemic levels (8.5% vs. 8.2%, P &amp;lt; 0.001), higher BW (97 vs. 93 kg, P &amp;lt; 0.001) and BMI (35 vs. 34 kg/m2, P &amp;lt; 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (−2.6% vs. −2.4%), BW (−14 vs. −13 kg), WC (−10 vs. −10 cm), triglycerides (−26% vs. −24%), HDL (7% vs. 7%), and systolic BP (−6 vs. −7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.
The Clinical Relevance of the Infiltrating Immune Cell Composition in Kidney Transplant Rejection
Authors: Thibaut Vaulet, Jasper Callemeyn, Baptiste Lamarthée, Asier Antoranz, Tim Debyser, Priyanka Koshy, Dany Anglicheau, Jill Colpaert, Wilfried Gwinner, Philip F. Halloran, Dirk Kuypers, Claire Tinel, Amaryllis Van Craenenbroeck, Elisabet Van Loon, Pierre Marquet, Francesca Bosisio, Maarten Naesens
Journal: Journal of the American Society of Nephrology (2024)

Key Points The estimated composition of immune cells in kidney transplants correlates poorly with the primary rejection categories defined by Banff criteria. Spatial cell distribution could be coupled with a detailed cellular composition to assess causal triggers for allorecognition. Intragraft CD8temra cells showed strong and consistent association with graft failure, regardless of the Banff rejection phenotypes. Background The link between the histology of kidney transplant rejection, especially antibody-mediated rejection, T-cell–mediated rejection, and mixed rejection, and the types of infiltrating immune cells is currently not well charted. Cost and technical complexity of single-cell analysis hinder large-scale studies of the relationship between cell infiltrate profiles and histological heterogeneity. Methods In this cross-sectional study, we assessed the composition of nine intragraft immune cell types by using a validated kidney transplant–specific signature matrix for deconvolution of bulk transcriptomics in three different kidney transplant biopsy datasets ( N =403, N =224, N =282). The association and discrimination of the immune cell types with the Banff histology and the association with graft failure were assessed individually and with multivariable models. Unsupervised clustering algorithms were applied on the overall immune cell composition and compared with the Banff phenotypes. Results Banff-defined rejection was related to high presence of CD8 + effector T cells, natural killer cells, monocytes/macrophages, and, to a lesser extent, B cells, whereas CD4 + memory T cells were lower in rejection compared with no rejection. Estimated intragraft effector memory–expressing CD45RA (TEMRA) CD8 + T cells were strongly and consistently associated with graft failure. The large heterogeneity in immune cell composition across rejection types prevented supervised and unsupervised methods to accurately recover the Banff phenotypes solely on the basis of immune cell estimates. The lack of correlation between immune cell composition and Banff-defined rejection types was validated using multiplex immunohistochemistry. Conclusions Although some specific cell types ( FCGR3A + myeloid cells, CD14 + monocytes/macrophages, and NK cells) partly discriminated between rejection phenotypes, the overall estimated immune cell composition of kidney transplants was ill related to main Banff-defined rejection categories and added to the Banff lesion scoring and evaluation of rejection severity. The estimated intragraft CD8temra cells bore strong and consistent association with graft failure and were independent of Banff-grade rejection.
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Authors: Vered Stearns, Opeyemi A. Jegede, Victor T.-S. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand, Atif Shafqat, Nisha L. Jacobs, William Luginbuhl, Paul Gilman, Al B. Benson, Judie R. Goodman, Gary L. Buchschacher, N. Lynn Henry, Charles L. Loprinzi, Patrick J. Flynn, Edith P. Mitchell, Michael J. Fisch, Joseph A. Sparano, Lynne I. Wagner
Journal: Clinical Cancer Research (2024)

Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohort study designed to validate the association between 10 SNPs and AI discontinuation due to AIMSS.
Association of Integrated Proteomic and Metabolomic Modules with Risk of Kidney Disease Progression
Authors: Pascal Schlosser, Aditya L. Surapaneni, Oleg Borisov, Insa M. Schmidt, Linda Zhou, Amanda Anderson, Rajat Deo, Ruth Dubin, Peter Ganz, Jiang He, Paul L. Kimmel, Hongzhe Li, Robert G. Nelson, Anna C. Porter, Mahboob Rahman, Hernan Rincon-Choles, Vallabh Shah, Mark L. Unruh, Ramachandran S. Vasan, Zihe Zheng, Harold I. Feldman, Sushrut S. Waikar, Anna Köttgen, Eugene P. Rhee, Josef Coresh, Morgan E. Grams
Journal: Journal of the American Society of Nephrology (2024)

Key Points Integrated analysis of proteome and metabolome identifies modules associated with CKD progression and kidney failure. Ephrin transmembrane proteins and podocyte-expressed CRIM1 and NPNT emerged as central components and warrant experimental and clinical investigation. Background Proteins and metabolites play crucial roles in various biological functions and are frequently interconnected through enzymatic or transport processes. Methods We present an integrated analysis of 4091 proteins and 630 metabolites in the Chronic Renal Insufficiency Cohort study ( N =1708; average follow-up for kidney failure, 9.5 years, with 537 events). Proteins and metabolites were integrated using an unsupervised clustering method, and we assessed associations between clusters and CKD progression and kidney failure using Cox proportional hazards models. Analyses were adjusted for demographics and risk factors, including the eGFR and urine protein–creatinine ratio. Associations were identified in a discovery sample (random two thirds, n =1139) and then evaluated in a replication sample (one third, n =569). Results We identified 139 modules of correlated proteins and metabolites, which were represented by their principal components. Modules and principal component loadings were projected onto the replication sample, which demonstrated a consistent network structure. Two modules, representing a total of 236 proteins and 82 metabolites, were robustly associated with both CKD progression and kidney failure in both discovery and validation samples. Using gene set enrichment, several transmembrane-related terms were identified as overrepresented in these modules. Transmembrane–ephrin receptor activity displayed the largest odds (odds ratio=13.2, P value = 5.5×10 −5 ). A module containing CRIM1 and NPNT expressed in podocytes demonstrated particularly strong associations with kidney failure ( P value = 2.6×10 −5 ). Conclusions This study demonstrates that integration of the proteome and metabolome can identify functions of pathophysiologic importance in kidney disease.
Comparative Long-Term Clinical Performance of Mechanical Aortic Valve Prostheses
Authors: Malin Granbom Koski, Natalie Glaser, Anders Franco-Cereceda, Ulrik Sartipy, Michael Dismorr
Journal: JAMA Network Open (2024)

Aggregated data and long-term follow-up in national health data registers offer the opportunity to compare the performance of mechanical aortic prostheses within the same population.
Self-Administered Acupressure for Probable Knee Osteoarthritis in Middle-Aged and Older Adults
Authors: Wing-Fai Yeung, Shu-Cheng Chen, Denise Shuk Ting Cheung, Carlos King-Ho Wong, Tsz Chung Chong, Yuen Shan Ho, Lorna Kwai Ping Suen, Lai Ming Ho, Lixing Lao
Journal: JAMA Network Open (2024)

The effects of self-administered acupressure (SAA) on knee osteoarthritis (OA) pain remain unclear.
Study: Roughly 1 in 8 Patients Wrongly Diagnosed With Pneumonia
Authors: Emily Harris
Journal: JAMA (2024)

Ashwin B. Gupta, MD; Scott A. Flanders, MD; Lindsay A. Petty, MD; Tejal N. Gandhi, MD; Michael S. Pulia, MD, PhD; Jennifer K. Horowitz, MA; David Ratz, MS; Steven J. Bernstein, MD, MPH; Anurag N. Malani, MD; Payal K. Patel, MD, MPH; Timothy P. Hofer, MD, MSc; Tanima Basu, MA, MS; Vineet Chopra, MD, MSc; Valerie M. Vaughn, MD, MSc
Understanding How Clinicians Personalize Fluid and Vasopressor Decisions in Early Sepsis Management
Authors: Elizabeth S. Munroe, Julien Weinstein, Hayley B. Gershengorn, Kevin J. Karlic, Sarah Seelye, Michael W. Sjoding, Thomas S. Valley, Hallie C. Prescott
Journal: JAMA Network Open (2024)

Recent sepsis trials suggest that fluid-liberal vs fluid-restrictive resuscitation has similar outcomes. These trials used generalized approaches to resuscitation, and little is known about how clinicians personalize fluid and vasopressor administration in practice.
Nationwide Association of Surgical Performance of Minimally Invasive Esophagectomy With Patient Outcomes
Authors: Mirte H. M. Ketel, Bastiaan R. Klarenbeek, Inger Abma, Eric H. J. Belgers, Peter-Paul L. O. Coene, Jan Willem T. Dekker, Peter van Duijvendijk, Marloes Emous, Suzanne S. Gisbertz, Jan Willem Haveman, Joos Heisterkamp, Grard A. P. Nieuwenhuijzen, Jelle P. Ruurda, Johanna W. van Sandick, Pieter C. van der Sluis, Marc J. van Det, Stijn van Esser, Simon Law, Wobbe O. de Steur, Meindert N. Sosef, Bas Wijnhoven, Gerjon Hannink, Camiel Rosman, Frans van Workum, Mark I. van Berge Henegouwen, Nannet Schuring, Misha Luye, Tessa Geraedts, Sjoerd Lagarde, Jean-Pierre Pierie, Daniël Hess, Koen J. Hartemink, Xander A.F.A. Veenhof, Merlijn Hutteman, Frederieke Dijkstra, Richard van Hillegersberg, Ewout A. Kouwenhoven, Bob Schaafsma
Journal: JAMA Network Open (2024)

Suboptimal surgical performance is hypothesized to be associated with less favorable patient outcomes in minimally invasive esophagectomy (MIE). Establishing this association may lead to programs that promote better surgical performance of MIE and improve patient outcomes.
Optimizing Outcomes in Minimally Invasive Resections of Colorectal Liver Metastases
Authors: Parit T. Mavani, Mihir M. Shah
Journal: JAMA Network Open (2024)

Friso B. Achterberg, MD; Okker D. Bijlstra, MD; Maxime D. Slooter, MD, PhD; Babs G. Sibinga Mulder, MD, PhD; Mark C. Boonstra, MD, PhD; Stefan A. Bouwense, MD, PhD; Koop Bosscha, MD, PhD; Mariëlle M. E. Coolsen, MD, PhD; Wouter J. M. Derksen, MD, PhD; Michael F. Gerhards, MD, PhD; Paul D. Gobardhan, MD, PhD; Jeroen Hagendoorn, MD, PhD; Daan Lips, MD, PhD; Hendrik A. Marsman, MD, PhD; Babs M. Zonderhuis, MD; Lissa Wullaert, MD; Hein Putter, PhD; Jacobus Burggraaf, MD, PhD; J. Sven D. Mieog, MD, PhD; Alexander L. Vahrmeijer, MD, PhD; Rutger-Jan Swijnenburg, MD, PhD; Dutch Liver Surgery Group
Video-Based Assessment of Surgical Quality—Will Video Kill the Radio Star?
Authors: Alexandra C. W. Reitz, Nader N. Massarweh
Journal: JAMA Network Open (2024)

Mirte H. M. Ketel, MSc; Bastiaan R. Klarenbeek, MD, PhD; Inger Abma, PhD; Eric H. J. Belgers, MD; Peter-Paul L. O. Coene, MD; Jan Willem T. Dekker, MD, PhD; Peter van Duijvendijk, MD, PhD; Marloes Emous, MD, PhD; Suzanne S. Gisbertz, MD, PhD; Jan Willem Haveman, MD, PhD; Joos Heisterkamp, MD, PhD; Grard A. P. Nieuwenhuijzen, MD, PhD; Jelle P. Ruurda, MD, PhD; Johanna W. van Sandick, MD, PhD; Pieter C. van der Sluis, MD, PhD; Marc J. van Det, MD, PhD; Stijn van Esser, MD, PhD; Simon Law, MD, PhD; Wobbe O. de Steur, MD, PhD; Meindert N. Sosef, MD, PhD; Bas Wijnhoven, MD, PhD; Gerjon Hannink, PhD; Camiel Rosman, MD, PhD; Frans van Workum, MD, PhD; MIE-CAT Netherlands Collaborative Group; Mark I. van Berge Henegouwen; Nannet Schuring; Misha Luye; Tessa Geraedts; Sjoerd Lagarde; Jean-Pierre Pierie; Daniël Hess; Koen J. Hartemink; Xander A.F.A. Veenhof; Merlijn Hutteman; Frederieke Dijkstra; Richard van Hillegersberg; Ewout A. Kouwenhoven; Bob Schaafsma
Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Authors: Tanner M. Johanns, Elizabeth A.R. Garfinkle, Katherine E. Miller, Alexandra J. Livingstone, Kaleigh F. Roberts, Lakshmi P. Rao Venkata, Joshua L. Dowling, Michael R. Chicoine, Ralph G. Dacey, Gregory J. Zipfel, Albert H. Kim, Elaine R. Mardis, Gavin P. Dunn
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Outcomes for patients with glioblastoma (GBM) remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options due to the lack of tumor immunogenicity. Several clinical trials have reported promising results with cancer vaccines. To date, studies have used data from a single tumor site to identify targetable antigens, but this approach limits the antigen pool and is antithetical to the heterogeneity of GBM. We have implemented multisector sequencing to increase the pool of neoantigens across the GBM genomic landscape that can be incorporated into personalized peptide vaccines called NeoVax. Patients and Methods: In this study, we report the findings of four patients enrolled onto the NeoVax clinical trial (NCT0342209). Results: Immune reactivity to NeoVax neoantigens was assessed in peripheral blood mononuclear cells pre- and post-NeoVax for patients 1 to 3 using IFNγ-ELISPOT assay. A statistically significant increase in IFNγ producing T cells at the post-NeoVax time point for several neoantigens was observed. Furthermore, a post-NeoVax tumor biopsy was obtained from patient 3 and, upon evaluation, revealed evidence of infiltrating, clonally expanded T cells. Conclusions: Collectively, our findings suggest that NeoVax stimulated the expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine–based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in patients with GBM.
A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Authors: Ji W. Han, Soon K. Lee, Jung H. Kwon, Soon W. Nam, Hyun Yang, Si H. Bae, Ji H. Kim, Heechul Nam, Chang W. Kim, Hae L. Lee, Hee Y. Kim, Sung W. Lee, Ahlim Lee, U I. Chang, Do S. Song, Seok-Hwan Kim, Myeong J. Song, Pil S. Sung, Jong Y. Choi, Seung K. Yoon, Jeong W. Jang
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Given its heterogeneity and diverse clinical outcomes, precise subclassification of Barcelona Clinic Liver Cancer stage C (BCLC-C) hepatocellular carcinoma (HCC) is required for appropriately determining patient prognosis and selecting treatment. Experimental Design: We recruited 2,626 patients with BCLC-C HCC from multiple centers, comprising training/test (n = 1,693) and validation cohorts (n = 933). The XGBoost model was chosen for maximum performance among the machine learning (ML) models. Patients were categorized into low-, intermediate-, high-, and very high-risk subgroups based on the estimated prognosis, and this subclassification was named the CLAssification via Machine learning of BCLC-C (CLAM-C). Results: The areas under the receiver operating characteristic curve of the CLAM-C for predicting the 6-, 12-, and 24-month survival of patients with BCLC-C were 0.800, 0.831, and 0.715, respectively—significantly higher than those of the conventional models, which were consistent in the validation cohort. The four subgroups had significantly different median overall survivals, and this difference was maintained among various patient subgroups and treatment modalities. Immune-checkpoint inhibitors and transarterial therapies were associated with significantly better survival than tyrosine kinase inhibitors (TKI) in the low- and intermediate-risk subgroups. In cases with first-line systemic therapy, the CLAM-C identified atezolizumab–bevacizumab as the best therapy, particularly in the high-risk group. In cases with later-line systemic therapy, nivolumab had better survival than TKIs in the low-to-intermediate-risk subgroup, whereas TKIs had better survival in the high- to very high-risk subgroup. Conclusions: ML modeling effectively subclassified patients with BCLC-C HCC, potentially aiding treatment allocation. Our study underscores the potential utilization of ML modeling in terms of prognostication and treatment allocation in patients with BCLC-C HCC.
ICG-Fluorescence Imaging for Margin Assessment During Minimally Invasive Colorectal Liver Metastasis Resection
Authors: Friso B. Achterberg, Okker D. Bijlstra, Maxime D. Slooter, Babs G. Sibinga Mulder, Mark C. Boonstra, Stefan A. Bouwense, Koop Bosscha, Mariëlle M. E. Coolsen, Wouter J. M. Derksen, Michael F. Gerhards, Paul D. Gobardhan, Jeroen Hagendoorn, Daan Lips, Hendrik A. Marsman, Babs M. Zonderhuis, Lissa Wullaert, Hein Putter, Jacobus Burggraaf, J. Sven D. Mieog, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg
Journal: JAMA Network Open (2024)

Unintended tumor-positive resection margins occur frequently during minimally invasive surgery for colorectal liver metastases and potentially negatively influence oncologic outcomes.
Shifts in Diagnostic Testing for Headache in the Emergency Department, 2015 to 2021
Authors: Dustin G. Mark, Brandon H. Horton, Mary E. Reed
Journal: JAMA Network Open (2024)

Subarachnoid hemorrhage is typically diagnosed by noncontrast head computed tomography (CT); lumbar puncture is recommended if computed tomography is nondiagnostic, although CT cerebral angiography has been promoted as an alternative to lumbar puncture in this diagnostic pathway. The outcomes of this debate in practice have not been studied.
Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals
Authors: Jeffrey R. Strich, Ahmed Mishuk, Guoqing Diao, Alexander Lawandi, Willy Li, Cumhur Y. Demirkale, Ahmed Babiker, Alex Mancera, Bruce J. Swihart, Morgan Walker, Christina Yek, Maniraj Neupane, Nathaniel De Jonge, Sarah Warner, Sameer S. Kadri, Jeffrey R. Strich, Ahmed Mishuk, Guoqing Diao, Alexander Lawandi, Willy Li, Cumhur Y. Demirkale, Ahmed Babiker, Alex Mancera, Bruce J. Swihart, Morgan Walker, Christina Yek, Maniraj Neupane, Nathaniel De Jonge, Sarah Warner, Sameer S. Kadri
Journal: Annals of Internal Medicine (2024)

The U.S. antibiotic market failure has threatened future innovation and supply. Understanding when and why clinicians underutilize recently approved gram-negative antibiotics might help prioritize the patient in future antibiotic development and potential market entry rewards.
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Authors: Michael Rade, Nora Grieb, Ronald Weiss, Jaren Sia, Luise Fischer, Patrick Born, Andreas Boldt, Stephan Fricke, Paul Franz, Jonathan Scolnick, Lakshmi Venkatraman, Stacy Xu, Christina Kloetzer, Simone Heyn, Anne Sophie Kubasch, Ronny Baber, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Jule Ussmann, Birthe Schetschorke, Saskia Hell, Sebastian Schwind, Klaus H. Metzeler, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Kristin Reiche, Vladan Vucinic, Maximilian Merz
Journal: Nature Cancer (2024)
Rapid molecular epidemiology investigations into two recent measles outbreaks in Israel detected from October 2023 to January 2024
Authors: Efrat Bucris, Victoria Indenbaum, Tal Levin, Yara Kanaaneh, Keren Friedman, Tatyana Kushnir, Rivka Sheffer, Michal Savion, Matanelle Salama, Noa Di-castro, Kozita Labay, Maya Butera, Baraah Shihada, Zohar Mor, Yaniv Lustig, Neta S. Zuckerman
Journal: Eurosurveillance (2024)

Between late 2023 and early 2024, two measles outbreaks occurred in Israel, each caused by importation of measles virus strains of respective B3 and D8 genotypes. In this study, we validate transmission pathways uncovered by epidemiological investigations using a rapid molecular approach, based on complete measles virus genomes. The presented findings support this rapid molecular approach in complementing conventional contact tracing and highlight its potential for informing public health interventions.
Single Cell Atlas: a single-cell multi-omics human cell encyclopedia
Authors: Lu Pan, Paolo Parini, Roman Tremmel, Joseph Loscalzo, Volker M. Lauschke, Bradley A. Maron, Paola Paci, Ingemar Ernberg, Nguan Soon Tan, Zehuan Liao, Weiyao Yin, Sundararaman Rengarajan, Xuexin Li
Journal: Genome biology (2024)

Abstract Single-cell sequencing datasets are key in biology and medicine for unraveling insights into heterogeneous cell populations with unprecedented resolution. Here, we construct a single-cell multi-omics map of human tissues through in-depth characterizations of datasets from five single-cell omics, spatial transcriptomics, and two bulk omics across 125 healthy adult and fetal tissues. We construct its complement web-based platform, the Single Cell Atlas (SCA, www.singlecellatlas.org ), to enable vast interactive data exploration of deep multi-omics signatures across human fetal and adult tissues. The atlas resources and database queries aspire to serve as a one-stop, comprehensive, and time-effective resource for various omics studies.
Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins
Authors: Meredith L. Stone, Jesse Lee, Jae W. Lee, Heather Coho, Mito Tariveranmoshabad, Max M. Wattenberg, Hana Choi, Veronica M. Herrera, Yuqing Xue, Shaanti Choi-Bose, Sofia K. Zingone, Dhruv Patel, Kelly Markowitz, Devora Delman, Vinod P. Balachandran, Gregory L. Beatty
Journal: Nature Immunology (2024)
A neurofunctional signature of subjective disgust generalizes to oral distaste and socio-moral contexts
Authors: Xianyang Gan, Feng Zhou, Ting Xu, Xiaobo Liu, Ran Zhang, Zihao Zheng, Xi Yang, Xinqi Zhou, Fangwen Yu, Jialin Li, Ruifang Cui, Lan Wang, Jiajin Yuan, Dezhong Yao, Benjamin Becker
Journal: Nature Human Behaviour (2024)